Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (QNRX) received FDA IND clearance to begin a Phase 2 study of QRX003 for Peeling Skin Syndrome, with study initiation expected in 2H 2026. The news is a positive regulatory milestone, but timing out to late-2026 limits near-term impact on valuation.

Analysis

Quoin Pharmaceuticals (QNRX) received FDA IND clearance to begin a Phase 2 study of QRX003 for Peeling Skin Syndrome, with study initiation expected in 2H 2026. The news is a positive regulatory milestone, but timing out to late-2026 limits near-term impact on valuation.